IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM) will report its financial and operating results for the nine months ended September 30, 2025 on Wednesday, November 19, 2025 before the Nasdaq opens.

The company will host a conference call and webcast to discuss results and corporate developments at 10:00 a.m. EST the same day. Dial-in numbers are provided for US and Israel/international participants, and a live webcast plus a recording will be available via the company links.

CAESAREA, Israel, Nov. 12, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2025 before the Nasdaq Stock Market opens on Wednesday, November 19, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day.

Conference call & webcast info:
Wednesday, November 19, 2025, at 10:00 am EST
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: ir.icecure-medical.com

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: its expected announcement of financial and operational results as of and for the nine months ended September 30, 2025 and hosting a conference call related to such results. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

IR Contact:
Michael Polyviou
investors@icecure-medical.com
732-232-6914

View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-third-quarter-2025-financial-and-operating-results-on-november-19-2025-302612810.html

SOURCE IceCure Medical

FAQ

When will IceCure Medical (ICCM) release its Q3 2025 results?

IceCure will issue results for the nine months ended September 30, 2025 on Wednesday, November 19, 2025 before Nasdaq opens.

What time is the IceCure (ICCM) conference call on November 19, 2025?

The conference call is scheduled for 10:00 a.m. EST on November 19, 2025.

How can investors join the IceCure (ICCM) November 19, 2025 webcast?

A live webcast will be available at https://www.veidan-conferenceing.com/icecure and a recording at ir.icecure-medical.com.

What phone numbers can be used to join the IceCure (ICCM) call on November 19, 2025?

US dial-in: 1-888-407-2553; Israel/International: +972-3-918-0696.

What period do IceCure's November 19, 2025 results cover?

The results cover the nine months ended September 30, 2025.

Will a replay of the IceCure (ICCM) November 19, 2025 webcast be available?

Yes, a recording will be available at ir.icecure-medical.com after the live webcast.